The Sulfur Question: MSM's Small, Slow Case for Aching Knees

The powder is white, faintly bitter, measured in grams. One and a half to six grams a day, stirred into water, morning after morning, for weeks. Across the room a clipboard waits: pain scores, function scores, the slow arithmetic of a placebo-controlled trial. The bottles in the blinded cabinet are identical; only the code sheet knows which held methylsulfonylmethane.

MSM — dimethyl sulfone, methyl sulfone — is a naturally occurring organosulfur compound found in small amounts in fresh vegetables, fruits, grains, and animal products, and manufactured synthetically for the supplement shelf. It is the oxidized metabolite of DMSO, a source of bioavailable sulfur, and in laboratory and animal work it shows anti-inflammatory and antioxidant behavior: inhibition of NF-κB signaling, dampening of NLRP3 inflammasome activation, support of glutathione and total antioxidant capacity. The question the clipboard exists to answer is whether any of that reaches a human knee.

The trials: significant, but small

The human literature centers on osteoarthritis. A 2006 pilot clinical trial in Osteoarthritis and Cartilage tested MSM against osteoarthritis pain of the knee. A 2023 randomized, double-blind, placebo-controlled trial in Nutrients reported that MSM improved knee quality of life in participants with mild knee pain. A 2018 systematic review and meta-analysis in the British Journal of Sports Medicine placed MSM inside the broader dietary-supplement evidence for osteoarthritis. Across these studies the pattern repeats: statistically significant but generally small reductions in joint pain and improvements in physical function — alone, or combined with glucosamine, chondroitin, or boswellic acids. The combinations deserve a flag: when MSM shares a capsule with three other ingredients, its isolated contribution gets harder to read.

Beyond the knee, small trials suggest MSM may attenuate post-exercise muscle and joint pain, oxidative stress, and inflammatory signaling, and it has been evaluated for seasonal allergic rhinitis — again small, again short. On safety the record is lighter reading: MSM is a GRAS substance, generally recognized as safe, and well tolerated at doses up to about 4 grams per day.

The limits deserve the same font size

The evidence is limited by small samples, short durations, and inconsistent results; several trials and evidence reviews report null findings or effects of uncertain clinical importance. That last phrase deserves translation: a result can clear a statistical bar and still be too small for a patient to feel. And the arithmetic of expectations matters — smaller and slower than NSAIDs means weeks to a modest effect, not days to a strong one. The trials that exist are the trials we judge by, and they are small. Nothing here indicts MSM; everything here caps the claim. Effects appear smaller and slower than NSAIDs. There is no evidence of disease modification — nothing in the human literature shows cartilage preserved or rebuilt — and no confirmed long-term benefit. 'Supports joint comfort' is a fairer summary than 'rebuilds cartilage', and the distance between those two sentences is exactly where supplement marketing likes to live. The evidence describes the compound methylsulfonylmethane and its mechanisms, not any specific commercial product.

Practically, MSM sits in the category of low-risk, modest-expectation supplements: plausible for someone with mild joint discomfort who wants a well-tolerated option and is willing to wait weeks to judge it, and no substitute for medical care of significant joint disease. Judged against the standard it actually met — statistically significant symptom improvement in small trials — it passes. Judged against the label language it attracts, it does not.

The clipboard fills in either way, week after week, gram after gram. What the arithmetic keeps saying is modest: a little less pain, a little more function, statistical significance without drama. Educational, not medical advice.